Sentences with phrase «advanced cell technology»
Twelve patients with Stargardt's Macular Dystrophy, which causes vision loss in children after the age of ten, will be enrolled in the combined Phase I / II (safety and effectiveness) clinical trial, announced Advanced Cell Technology of Marlborough, Mass..
http://www.robertlanza.com/
Robert Lanza is the chief scientist of Advanced Cell Technology (ACTC), a company whose scientific achievements are overshadowed only by its history of desperate business decisions.
September 22, 2010, MARLBOROUGH, MA â $ «(PR Newswire) Advanced Cell Technology, Inc. (â $ œACTâ $; OTCBB: ACTC) announced today that the companyâ $ ™ s Chief Scientific Officer, Robert Lanza, MD, and Kwang - Soo Kim, PhD, of Harvard University and McLean Hospital, have won a National Institutes of Health (NIH) Directorâ $ ™ s Opportunity Award for research in â $ œTranslating Basic Science Discoveries into New and Better Treatmentsâ $ under the American Recovery & Reinvestment Act of 2009.
Biologist Robert Lanza of Advanced Cell Technology in Worcester, Mass., reports his team's findings in this week's issue of the journal Nature.
The new advance comes from the laboratory of biologist Robert Lanza of Advanced Cell Technology in Worcester, Mass..
This cell culture was generated by Advanced Cell Technology, Inc. (now Ocata Therapeutics).
Advanced Cell Technology, of Marlborough, Mass., said it would test its stem cell therapy on 12 adults with severe vision loss caused by Stargardt's, an inherited disease.
«Before I did the #icebucketchallenge, I challenged the leader of Advanced Cell Technology (ACT), Dr. Bob Lanza, to do the Ice Bucket Challenge.
They were financed by Advanced Cell Technology, a biotech company with laboratories in Marlborough, Massachusetts, that recently won approval from the U.S. Food and Drug Administration to test the treatment in 24 patients suffering from either dry advanced macular degeneration, or a juvenile form of the disease known as Stargardt's.
«In a report published in the journal Lancet, scientists led by Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology, provide the first evidence that stem cells from human embryos can be a safe and effective source of therapies for two types of eye diseases»
Lanza, the chief scientific officer at Advanced Cell Technology, and colleagues shared the optimism about iPS cells.
Currently, Robert Lanza is Head of Astellas Global Regenerative Medicine, and is Chief Scientific Officer of the Astellas Institute for Regenerative Medicine and (formerly Ocata Therapeutics / Advanced Cell Technology), and Adjunct Professor at Wake Forest University School of Medicine.
Advanced Cell Technology, a biotechnology company based in Santa Monica., Calif., said the research should begin early next year, following the green light from the U.S. Food and Drug Administration.
Advanced Cell Technology, a Santa Monica - based biotechnology company, is seeking FDA approval to use such derived cells to treat Stargardt's macular dystrophy, after studies in rats showed that the cells could restore vision.
A trial being conducted by Advanced Cell Technology is testing the effectiveness of MA09 - hRPE, human ESCs terminally differentiated into retinal pigment epithelial (RPE) cells, in treating degenerative macular diseases.
A team led by Steven Schwartz at UCLA administered about 50,000 cells Tuesday into one eye of a volunteer suffering from Stargardt Macular Dystrophy, a progressive form of blindness that usually begins in childhood, and another with Dry Age - Related Macular Degeneration, the leading cause of blindness in the developed world, Advanced Cell Technology, which is sponsoring the study, announced Thursday.
In April of last year, the US Food and Drug Administration invited three large biotech companies - Geron, Advanced Cell Technology, and Novocell - to testify about how to safely test human embryonic stem cell (ESC) products in patients.
Human embryonic stem cellsImage: Wikimedia commons, Nissim Benvenistylinkurl: Advanced Cell Technology; http://www.advancedcell.com/ (ACT) filed an Investigational New Drug (IND) application yesterday (November 18) to conduct a phase I / II trial using hESCs to treat a genetic eye disease.
Advanced Cell Technology (ACT) just release a two cases report for treatment of for macular degeneration.
Advanced Cell Technology is trying to treat Stargadt's Macular Dystrophy, a disease which affects 25,000 people in the US and can leave victims blinded as children.
Advanced Cell Technology (ACT), based in Marlborough, Mass., will begin testing its retinal cell treatment this year in a dozen patients with Stargardt's macular dystrophy, an inherited degenerative eye disease that leads to blindness in children.
Advanced Cell Technology (OTC: ACTC, US) The whole world is eagerly watching the first results of clinical trials, involved embryonic stem cells.
Robert Lanza, chief scientific officer at Advanced Cell Technology, likens it to «turning lead into gold.»
Dr. David T. Scadden, professor of medicine at Harvard University, and Dr. Robert Lanza, vice president of research and scientific development for Advanced Cell Technology, well also be featured.
Earlier this year, scientists at University of California, Los Angeles, and Advanced Cell Technology of Marlborough, Massachusetts, reported in The Lancet about the safe and successful use of RPE cells derived from human embryonic stem cells, rather than iPS cells, to treat a different type of AMD in a limited number of human patients.
«After a few more flight tests — in order to assure everything is working properly — it should be ready for commercial use,» claims co-author Robert Lanza of Advanced Cell Technology Inc. in Worcester, Massachusetts, in a press release.
The letter was written and circulated by researchers Robert Lanza and Michael West of Advanced Cell Technology, a biotechnology company in Worcester, Massachusetts.
Robert Lanza, vice president of medical and scientific development at the privately - held biotechnology company Advanced Cell Technology (ACT), says that without scientific data, he is extremely skeptical of the group's claim.
«This is an impressive study» which «clears up a longstanding scientific question,» says Robert Lanza, medical director of Advanced Cell Technology in Worcester, Massachusetts.
«This unequivocally shows you can generate stem cells from primates, and we're primates,» says stem cell biologist Robert Lanza, chief scientific officer of the Worcester, Mass., company Advanced Cell Technology, who was not involved in the research.
«It's a great success,» says Philip Damiani, a reproductive physiologist at Advanced Cell Technology in Worcester, Massachusetts.
«The goal is not to put the Red Cross out of business,» says Robert Lanza, chief scientific officer at Advanced Cell Technology, the company that developed the process.
The Korean trial was a collaborative effort between scientists at CHA University and stem cell pioneer Robert Lanza at Ocata Therapeutics (formerly known as Advanced Cell Technology).
At Advanced Cell Technology, Lanza uses stem cells to prevent or treat blindness.
«Regulatory agencies would be very concerned that ChR2 DNA was found in tissues outside of the treated eye,» says Robert Lanza, of Advanced Cell Technology in Worcester, Massachusetts.
In 2008 a group of medical researchers led by Robert Lanza at Advanced Cell Technology in Worcester, Massachusetts, reported another leap: They discovered a way to avoid destroying the embryo by deriving an entire stem cell line from a single embryonic cell.
Something as simple as an unsterilized milk bottle may have transmitted the bug, say researchers at Advanced Cell Technology in Worcester, Massachusetts, which created Noah.
Scientists at the biotechnology firm Advanced Cell Technology in Worcester, Mass., have generated a more abundant source of RPE cells.
Stemagen's team says that's next, but Robert Lanza of Advanced Cell Technology in Worcester, Massachusetts, doubts the researchers could do it with the embryos they have created so far.
The team makes it clear that it thinks its approach is superior to one reported last month in Nature by scientists at Advanced Cell Technology (ACT) in California — deriving an ES cell line from a single cell taken from a morula (ScienceNOW 23 August).
After Hwang's papers were published, Advanced Cell Technology had to suspend its research in the area; funding had dried up, and the company's egg supplier had cut off its shipments, saying that the goal had already been achieved.
«The goal is to halt the rate of photoreceptor loss,» says Robert Lanza, chief scientist at Advanced Cell Technology (ACT) of Worcester, Massachusetts, the company that has been developing the treatment since first turning hESCs into RPEs in 2004.
With a history of public blunders, can Advanced Cell Technology make embryonic stem - cell therapies a reality?
«The time is coming when we'll repair heart tissue after a heart attack and restore blood flow to limbs that would otherwise be amputated,» says stem cell researcher Robert Lanza of Advanced Cell Technology in Massachusetts.
«It's premature to abandon ESCs until we understand what's going on with iPSCs,» says Robert Lanza, chief scientist at Advanced Cell Technology in Massachusetts.
Advanced Cell Technology, for its part, has initiated dozens of clone pregnancies in cows and some in pigs.
Then, a team led by Robert Lanza, the chief scientific officer of Advanced Cell Technology Inc. in Marlborough, Massachusetts, and his colleagues published the first results ever of a clinical trial using human embryonic stem cells.
At least two U.S. companies — ABS Global of De Forest, Wisc., and Advanced Cell Technology of Worcester, Mass. — have successfully impregnated cows and pigs using cloned cells.
«Advanced Cell Technology has the ability to produce transgenic animals using fetal fibroblast nuclear transfer,» claims Steve Parkinson, president and chief executive officer.
He reports that Advanced Cell Technology plans to clone genetically altered animals whose neural tissue would be immunologically compatible with that of humans.